Ghrelin and Synthetic GH Secretagogues Protect Rat Hearts From Ischemic Damage
Ghrelin and synthetic GH secretagogues (hexarelin, EP-80317) protected rat hearts from ischemia-reperfusion injury, improving contractile recovery through effects on coronary perfusion pressure.
Quick Facts
What This Study Found
Ghrelin, hexarelin, and EP-80317 improved cardiac contractile recovery after ischemia in isolated rat hearts, with effects on coronary perfusion pressure, while MK-677 showed less cardioprotection — suggesting peptide GHS are preferred cardiac protectants.
Key Numbers
How They Did This
In-vitro isolated rat heart (Langendorff) study. Ghrelin, hexarelin, EP-80317, and MK-677 tested before or during ischemia-reperfusion. Cardiac contractile function and coronary perfusion pressure measured.
Why This Research Matters
Demonstrating that peptide GH secretagogues are better cardioprotectants than non-peptide MK-677 guides drug selection for cardiac applications and suggests a peptide-preferring cardiac receptor.
The Bigger Picture
Not all GH secretagogues are equal for cardiac protection. The peptide compounds' superiority suggests the cardiac receptor (possibly CD36) has different ligand preferences than the pituitary GHS-R.
What This Study Doesn't Tell Us
Isolated rat heart model. The specific cardiac receptor mediating protection was not definitively identified. Short-term ischemia protocol.
Questions This Raises
- ?Does the cardiac receptor prefer peptide over non-peptide ligands?
- ?Could hexarelin or EP-80317 be developed specifically as cardiac drugs?
- ?Does the coronary vascular effect explain the contractile protection?
Trust & Context
- Key Stat:
- Peptides > non-peptide Peptide GH secretagogues outperformed MK-677 for cardiac protection — the heart's receptor prefers peptide ligands
- Evidence Grade:
- Preliminary in-vitro evidence from isolated heart experiments comparing multiple GH secretagogues for cardioprotection.
- Study Age:
- Published in 2003. The cardiac GH secretagogue receptor (linked to CD36) has been further characterized with peptide preference confirmed.
- Original Title:
- Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart.
- Published In:
- Basic research in cardiology, 98(6), 401-5 (2003)
- Database ID:
- RPEP-00817
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Which GH peptides protect the heart best?
Peptide compounds (ghrelin, hexarelin, EP-80317) outperformed the non-peptide MK-677. The heart's protective receptor appears to prefer peptide ligands.
Why would the heart prefer peptide GH drugs?
The heart may have a different receptor (possibly CD36) than the pituitary (GHS-R1a). This cardiac receptor seems to respond better to peptide-shaped molecules, making peptide GH secretagogues better cardioprotectants.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00817APA
Frascarelli, Sabina; Ghelardoni, Sandra; Ronca-Testoni, Simonetta; Zucchi, Riccardo. (2003). Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart.. Basic research in cardiology, 98(6), 401-5.
MLA
Frascarelli, Sabina, et al. "Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart.." Basic research in cardiology, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Effect of ghrelin and synthetic growth hormone secretagogues..." RPEP-00817. Retrieved from https://rethinkpeptides.com/research/frascarelli-2003-effect-of-ghrelin-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.